1-(thiophen-3-yl)cyclopropane-1-carbonitrile | 162959-99-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: 1-(thiophen-3-yl)cyclopropane-1-carbonitrile
• 英文别名: 1-(3-Thienyl)cyclopropanecarbonitrile；1-thiophen-3-ylcyclopropane-1-carbonitrile
• CAS: 162959-99-1
• 化学式: C₈H₇NS
• 分子量: 149.216
• InChiKey: BQPOWBNNEAXARZ-UHFFFAOYSA-N

物化性质

• 沸点：
  288.2±23.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  52
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(thiophen-3-yl)cyclopropane-1-carbonitrile 在 lithium hydroxide monohydrate 作用下， 以80 %的产率得到1-(thiophen-3-yl)cyclopropane-1-carboxylic acid
  参考文献：
  名称：

  多环类衍生物受体激动剂、其制备方法和应用

  摘要：

  本发明涉及多环类衍生物受体激动剂、其制备方法和应用。特别地，本发明涉及通式(I)所示的化合物、其制备方法及含有该化合物的药物组合物，及其作为TAAR1受体激动剂在治疗、预防或控制神经障碍类疾病的用途，其中通式(I)中的各取代基与说明书中的定义相同。

  公开号：

  CN115433205A
• 作为产物：
  描述：

  3-噻吩乙腈 、 1-溴-2-氯乙烷 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 以69.3 %的产率得到1-(thiophen-3-yl)cyclopropane-1-carbonitrile
  参考文献：
  名称：

  [EN] SPIRO-CONTAINING DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF
  [FR] DÉRIVÉ CONTENANT UN SPIRO, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
  [ZH] 含螺环类衍生物、其制备方法和应用

  摘要：

  一种含螺环类衍生物、其制备方法和应用。特别地，通式(I)所示的化合物、其制备方法及含有该化合物的药物组合物，及其在制备预防和/或治疗与哺乳动物5-羟色胺受体和/或痕量胺相关受体和/或多巴胺受体相关的中枢神经系统疾病药物中的应用。

  公开号：

  WO2022206706A1

文献信息

• Methods and Compositions for Selectin Inhibition
  申请人：Kaila Neelu

  公开号：US20080255192A1

  公开（公告）日：2008-10-16

  The present teachings relate to novel compounds of formula I: wherein the constituent variables are as defined herein. Compounds of the present teachings can act as antagonists of the mammalian adhesion proteins known as selecting. Methods for treating or preventing selectin-mediated disorders are provided, which include administration of these compounds in a therapeutically effective amount.

  本教学涉及到式I的新化合物： 其中组成变量如本文所定义。本教学的化合物可以作为被称为选择素的哺乳动物粘附蛋白的拮抗剂。提供了治疗或预防选择素介导的疾病的方法，包括以治疗有效剂量给予这些化合物。
• Therapeutic agents
  申请人：Knoll Aktiengesellschaft

  公开号：US05804586A1

  公开（公告）日：1998-09-08

  Tetrahydroisoquinoline compounds of formula I ##STR1## and pharmaceutically acceptable salts thereof, in which: R.sub.1 represents one or more substituents selected from H, halo, hydroxy, alkyl (optionally substituted by hydroxy), alkoxy, alkylthio, alkylsulphinyl, alkyl-sulphonyl, nitro, cyano, polyhaloalkyl, polyhaloalkoxy, phenyl (optionally substituted by one or more of halo, alkyl or alkoxy), or R.sub.1 is optionally alkylated carbamoyl; R.sub.2 represents a saturated or unsaturated aliphatic group optionally substituted by hydroxy or alkoxy; E represents an alkylene chain optionally substituted by one or more alkyl groups; and G represents (a) optionally substituted saturated or unsaturated alicyclic group containing 3 to 8 carbon atoms, or (b) optionally substituted saturated or unsaturated aliphatic chain containing 1 to 12 carbon atoms, or (c) optionally substituted 5 or 6 membered heterocyclic ring containing one or more N or O atoms or SO.sub.n groups in which n is 0, 1 or 2; and O-acylated derivatives thereof which provide lipophilic esters have utility in analgesia or in the treatment of psychoses (e.g. schizophrenia), Parkinson's disease, Lesch-Nyan syndrome, attention deficit disorder or cognitive impairment or in the relief of drug dependence or tardive dyskinesia.

  Tetrahydroisoquinoline化合物的化学式I ##STR1## 及其药用可接受的盐，其中：R.sub.1代表H、卤素、羟基、烷基（可选择地被羟基取代）、烷氧基、烷基硫醚、烷基磺醇、烷基磺酰基、硝基、氰基、多卤代烷基、多卤代烷氧基、苯基（可选择地被一个或多个卤素、烷基或烷氧基取代），或R.sub.1可选择地被烷基化的氨基甲酰基；R.sub.2代表饱和或不饱和的烷基基团，可选择地被羟基或烷氧基取代；E代表一个烷基链，可选择地被一个或多个烷基基团取代；G代表（a）可选择地被取代的饱和或不饱和脂环基团，含有3至8个碳原子，或（b）可选择地被取代的饱和或不饱和脂肪链，含有1至12个碳原子，或（c）可选择地被取代的含有一个或多个N或O原子或SO.sub.n基团（其中n为0、1或2）的5或6元杂环环，以及提供亲脂性酯的O-酰化衍生物，在镇痛或治疗精神病（如精神分裂症）、帕金森病、莱施-尼恩综合征、注意力缺陷障碍或认知障碍或在缓解药物依赖或迟发性运动障碍方面具有用途。
• Isoquinoline derivatives as therapeutic agents
  申请人：Knoll Aktiengesellschaft

  公开号：US05807868A1

  公开（公告）日：1998-09-15

  Tetrahydroisoquinoline compounds of formula I ##STR1## and pharmaceutically acceptable salts thereof, in which: R.sub.1 represents one or more substituents selected from H, halo, hydroxy, alkyl (optionally substituted by hydroxy), alkoxy, alkylthio, alkylsulphinyl, alkyl-sulphonyl, nitro, cyano, polyhaloalkyl, polyhaloalkoxy, phenyl (optionally substituted by one or more of halo, alkyl or alkoxy), or R.sub.1 is optionally alkylated carbamoyl; R.sub.2 represents a saturated or unsaturated aliphatic group optionally substituted by hydroxy or alkoxy; E represents an alkylene chain optionally substituted by one or more alkyl groups; and G represents (a) optionally substituted saturated or unsaturated alicyclic group containing 3 to 8 carbon atoms, or (b) optionally substituted saturated or unsaturated aliphatic chain containing 1 to 12 carbon atoms, or (c) optionally substituted 5 or 6 membered heterocyclic ring containing one or more N or O atoms or SO.sub.n groups in which n is 0, 1 or 2; and O-acylated derivatives thereof which provide lipophilic esters have utility in analgesia or in the treatment of psychoses (e.g. schizophrenia), Parkinson's disease, Lesch-Nyan syndrome, attention deficit disorder or cognitive impairment or in the relief of drug dependence or tardive dyskinesia.

  公式I的四氢异喹啉化合物及其药学上可接受的盐，其中：R.sub.1代表一个或多个取代基，包括H，卤素，羟基，烷基（可选地被羟基取代），烷氧基，烷基硫基，烷基亚磺酰基，烷基磺酰基，硝基，氰基，多卤代烷基，多卤代烷氧基，苯基（可选地被一个或多个卤素，烷基或烷氧基取代），或R.sub.1可选择烷基化的氨基甲酰基；R.sub.2代表一个饱和或不饱和的脂肪族基团，可选地被羟基或烷氧基取代；E代表一个烷基链，可选地被一个或多个烷基取代；G代表（a）可选地取代的饱和或不饱和的脂环族基团，其中含有3至8个碳原子，或（b）可选地取代的饱和或不饱和的脂肪链，其中含有1至12个碳原子，或（c）可选地取代的5或6元杂环环，其中含有一个或多个N或O原子或SO.sub.n基团，其中n为0、1或2；以及提供亲脂性酯的O-酰化衍生物在镇痛或治疗精神病（例如精神分裂症）、帕金森病、Lesch-Nyan综合征、注意力缺陷障碍或认知障碍或缓解药物依赖或迟发性运动障碍方面具有用途。
• 并环类衍生物、其制备方法、中间体和应用
  申请人：[en]SHUJING BIOPHARMA CO., LTD;[zh]上海枢境生物科技有限公司

  公开号：WO2024120505A1

  公开（公告）日：2024-06-13

  本发明涉及并环类衍生物、其制备方法、中间体和应用。特别地，本发明涉及通式(I)所示的化合物、其制备方法、中间体、包含该并环类衍生物的药物组合物，以及该并环类衍生物或其药物组合物在制备预防和/或治疗与哺乳动物痕量胺相关受体和/或5-羟色胺受体和/或多巴胺受体相关的中枢神经系统疾病药物中的应用。
• Discovery of 2-[1-(4-Chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic Acid (PSI-421), a P-Selectin Inhibitor with Improved Pharmacokinetic Properties and Oral Efficacy in Models of Vascular Injury
  作者：Adrian Huang、Alessandro Moretto、Kristin Janz、Michael Lowe、Patricia W. Bedard、Steve Tam、Li Di、Valerie Clerin、Natalia Sushkova、Boris Tchernychev、Desiree H. H. Tsao、James C. Keith、Gray D. Shaw、Robert G. Schaub、Qin Wang、Neelu Kaila

  DOI：10.1021/jm9013696

  日期：2010.8.26

  Previously, we reported the discovery of PSI-697 (1a), a C-2 benzyl substituted quinoline salicylic acid-based P-selectin inhibitor. It is active in a variety of animal models of cardiovascular disease. Compound 1a has also been shown to be well tolerated and safe in healthy volunteers at doses of up to 1200 mg in a phase 1 single ascending dose study. However, its oral bioavailability was low. Our goal was to identify a back up compound with equal potency, increased solubility, and increased exposure. We expanded our structure activity-studies in this series by branching at the alpha position of the C-2 benzyl side chain and through modification of substituents on the carboxylic A-ring of the quinoline. This resulted in discovery of PSI-421 with marked improvement in aqueous solubility and pharmacokinetic properties. This compound has shown oral efficacy in animal models of arterial and venous injury and was selected as a preclinical development compound for potential treatment of such diseases as atherosclerosis and deep vein thrombosis.